• 9 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme
    Glioblastoma multiforme (GBM) is known as the most aggressive and prevalent brain tumor with a high mortality rate. It is reported in people who are as young as 10 years old to as old as over 70 years old, exhibiting inter and int [...] Read more.
    Manisha Singh ... Rachana
    Published: December 30, 2022 Explor Target Antitumor Ther. 2022;3:866–888
    DOI: https://doi.org/10.37349/etat.2022.00118
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:1320
    Download:51
    Times Cited: 0
    Open Access
    Original Article
    Evaluating immune response in vitro in a relevant microenvironment: a high-throughput microfluidic model for clinical screening
    Aim: Functional screening of new pharmaceutical compounds requires clinically relevant models to monitor essential cellular and immune responses during cancer progression, with or without treatment. Beyond survival, the emergence  [...] Read more.
    Flora Doffe ... Pierre Savagner
    Published: December 29, 2022 Explor Target Antitumor Ther. 2022;3:853–865
    DOI: https://doi.org/10.37349/etat.2022.00117
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:1311
    Download:65
    Times Cited: 0
    Open Access
    Commentary
    De novo cholesterol biosynthesis: an additional therapeutic target for the treatment of postmenopausal breast cancer with excessive adipose tissue
    The onset and development of breast cancer in postmenopausal women are associated with closely related individual-dependent factors, including weight gain and high levels of circulating androgens. Adipose tissue is the most periph [...] Read more.
    Danila Coradini
    Published: December 28, 2022 Explor Target Antitumor Ther. 2022;3:841–852
    DOI: https://doi.org/10.37349/etat.2022.00116
    Open Access
    Original Article
    Dendritic cell-targeting chemokines inhibit colorectal cancer progression
    Aim: Recent progress in cancer immunotherapy has shown its promise and prompted researchers to develop novel therapeutic strategies. Dendritic cells (DCs) are professional antigen-presenting cell [...] Read more.
    Pengkun Yuan ... Bin Ma
    Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:828–840
    DOI: https://doi.org/10.37349/etat.2022.00115
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:1204
    Download:27
    Open Access
    Perspective
    Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
    Among the malignant tumors in the central nervous system (CNS), glioma is the most challenging tumor to the public society, which accounts for the majority of intracranial malignant tumors with impa [...] Read more.
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:817–827
    DOI: https://doi.org/10.37349/etat.2022.00114
    This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
    View:3070
    Download:1354
    Open Access
    Review
    Artificial intelligence in breast cancer imaging: risk stratification, lesion detection and classification, treatment planning and prognosis—a narrative review
    The advent of artificial intelligence (AI) represents a real game changer in today’s landscape of breast cancer imaging. Several innovative AI-based tools have been developed and validated in recent years that promise to acceler [...] Read more.
    Maurizio Cè ... Michaela Cellina
    Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:795–816
    DOI: https://doi.org/10.37349/etat.2022.00113
    This article belongs to the special issue Artificial Intelligence for Precision Oncology
    View:1840
    Download:62
    Open Access
    Review
    Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
    Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies treatment, designed to provide superior efficacy and specific targeting of tumor cells, compared to systemic cyt [...] Read more.
    Marilia Barreca ... Francesco Bertoni
    Published: December 26, 2022 Explor Target Antitumor Ther. 2022;3:763–794
    DOI: https://doi.org/10.37349/etat.2022.00112
    This article belongs to the special issue Antibody-Drug Conjugates
    View:1820
    Download:62
    Open Access
    Review
    Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
    Major advances in cancer treatment have emerged with the introduction of immunotherapies using blocking antibodies that target T-cell inhibitory receptors, such as programmed death-1 (PD-1) and cyto [...] Read more.
    Mohamad Omar Ashi ... Stéphanie Corgnac
    Published: December 22, 2022 Explor Target Antitumor Ther. 2022;3:746–762
    DOI: https://doi.org/10.37349/etat.2022.00111
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:1390
    Download:56
    Times Cited: 0
    Open Access
    Systematic Review
    Diffusion-weighted imaging and apparent diffusion coefficient mapping of head and neck lymph node metastasis: a systematic review
    Aim: Head and neck squamous cell cancer (HNSCC) is the ninth most common tumor worldwide. Neck lymph node (LN) status is the major indicator of prognosis in all head and neck cancers, and the early detection of LN involvement is c [...] Read more.
    Maria Paola Belfiore ... Salvatore Cappabianca
    Published: December 13, 2022 Explor Target Antitumor Ther. 2022;3:734–745
    DOI: https://doi.org/10.37349/etat.2022.00110
    This article belongs to the special issue Artificial Intelligence for Precision Oncology
    View:1744
    Download:34